AOA
AOA Dx is a biotechnology company pioneering early cancer detection focused on women's health through an AI-enabled multi-omics platform. Their key products include GlycoLocate™, a revolutionary platform utilizing tumor marker gangliosides and complementary biomarkers with data science for early cancer detection, and AKRIVIS GD™, a novel blood test using AI and multi-omics to detect early-stage ovarian cancer. Founded in 2020, the company has raised significant funding rounds, expanded its team, and opened lab facilities in Denver, CO. AOA Dx differentiates itself by commercializing innovative biomarkers and AI technology to transform early cancer diagnostics, aiming to improve clinical practice and patient outcomes globally.
AOA
AOA Dx is a biotechnology company pioneering early cancer detection focused on women's health through an AI-enabled multi-omics platform. Their key products include GlycoLocate™, a revolutionary platform utilizing tumor marker gangliosides and complementary biomarkers with data science for early cancer detection, and AKRIVIS GD™, a novel blood test using AI and multi-omics to detect early-stage ovarian cancer. Founded in 2020, the company has raised significant funding rounds, expanded its team, and opened lab facilities in Denver, CO. AOA Dx differentiates itself by commercializing innovative biomarkers and AI technology to transform early cancer diagnostics, aiming to improve clinical practice and patient outcomes globally.